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History of Depression and Smoking Cessation Outcome: A Meta-Analysis
Brian Hitsman and Belinda Borrelli

Dennis E. McChargue and Bonnie Spring

Centers for Behavioral and Preventive Medicine, Brown
Medical School/The Miriam Hospital

University of Illinois at Chicago/Hines Veterans Affairs
Hospital, Maywood, Illinois

Raymond Niaura
Centers for Behavioral and Preventive Medicine, Brown Medical School/The Miriam Hospital

The authors conducted a meta-analysis of published studies to (a) evaluate the premise that a history of
major depression is associated with failure to quit smoking and (b) identify factors that moderate the
relationship between history of depression and cessation outcome. Fifteen studies met the selection
requirements and were coded for various study methodology and treatment characteristics. DSTAT was
used to calculate individual study effect sizes, determine the mean effect size across studies, and test for
moderator effects. No differences in either short-term (ⱕ 3 months) or long-term abstinence rates (ⱖ 6
months) were observed between smokers positive versus negative for history of depression. Lifetime
history of major depression does not appear to be an independent risk factor for cessation failure in
smoking cessation treatment.

an impediment to smoking cessation emerged in the late 1980s.
Glassman et al. (1988) first offered that interpretation after observing that 57% of smokers who lacked a history of depression
remained abstinent after 4 weeks of treatment, as compared with
33% of those who were history positive. Subsequent studies by
Glassman and colleagues showed that the negative effect of depression on quitting persisted even after the influence of other
psychiatric comorbidities had been controlled (Glassman et al.,
1990). Moreover, abstinence rates were lower among female
smokers with recurrent episodes of depression (5%), as compared
with those with single episodes (35%) (Covey, Glassman, Stetner,
& Becker, 1993).
The belief that a history of depression greatly decreases the
likelihood of quitting smoking has been widely promoted (Anda et
al., 1990; Glassman, 1993; Glassman, Covey, Stetner, & Rivelli,
2001; Kinnunen, Henning, & Nordstrom, 1999). The strength of
this conviction is illustrated by the extent to which attention has
turned to identifying the mechanisms by which a history of depression interferes with achieving abstinence. Hypothesized mechanisms include heightened pretreatment dysphoria (Covey, Glassman, & Stetner, 1990), heightened dysphoria following a quit
attempt (Ginsberg, Hall, Reus, & Muñoz, 1995), or recurrence of
depression prompted by acute abstinence (Borrelli et al., 1996;
Glassman et al., 2001). An additional process hypothesized to
increase risk of relapse is the tendency of depression-vulnerable
smokers to smoke during dysphoric states (Lerman et al., 1996).
Although it is generally assumed that a history of depression is
a barrier to quitting smoking, contradictory evidence also exists
(Ginsberg et al., 1995; Hall et al., 1996; Killen et al., 2000; Niaura
et al., 1999). We conducted a meta-analysis of the published
literature in an attempt to reconcile the conflicting findings concerning the influence of a depression history on smoking cessation.
Our primary aim was to evaluate the premise that history of
depression is associated with difficulty quitting. We hypothesized
that smokers positive for a history of depression would show

A widespread theory, expressed as the “hardening hypothesis,”
is that the current population of smokers has become increasingly
refractory to quitting (Hughes, 1996; Irvin & Brandon, 2000). The
inference is that those who continue to smoke despite strong social
pressures to quit possess attributes that make it especially difficult
to stop smoking. One such factor may be a history of major
depression. The hypothesis that a history of depression constitutes
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significantly lower abstinence rates than smokers negative for a
history of depression. A secondary aim was to test whether gender,
study methodology, or treatment factors moderated the association
between history of depression and smoking cessation.

Method
Literature Search
We conducted the computerized literature review using Medline (1966 –
2000) and PsycLIT (1971–2000) databases. Two separate searches were
performed within each database. We first searched using the keywords
depression and smoking. In our second search, we used the keywords mood
and smoking. In addition, we conducted a manual search of journals most
likely to have published original articles on depression and smoking
cessation. We restricted the manual search to articles published in the
following journals in the year 2000: Journal of Consulting and Clinical
Psychology, Archives of General Psychiatry, American Journal of Psychiatry, Addiction, Addictive Behaviors, Experimental and Clinical Psychopharmacology, Journal of Substance Abuse, and Health Psychology. As a
final step, we wrote 26 investigators requesting in press studies on depression and quitting smoking. Individuals were selected from the membership
of the Society for Research on Nicotine and Tobacco (2000) on the basis
of their having conducted prior research on mood and smoking.

Selection Requirements
Articles identified through our literature search (n ⫽ 1,301), including
the one in-press study received in response to our letter, were evaluated
further to determine whether they met our inclusion criteria. To be selected,
studies were required to have (a) a valid assessment of history of depression (i.e., no single-item assessments) and (b) a measure of smoking
cessation outcome. They also were required to be written in English.
Because our focus was on smokers’ ability to achieve abstinence, we
excluded studies in which outcome was defined as smoking reduction or
lapse and studies involving retrospective recall of quitting. In addition, case
studies were excluded because an effect size cannot be derived from
single-subject designs.
Fifteen of 18 studies identified were included in our meta-analysis.
Three met our exclusion criteria. Two studies by Cornelius and colleagues
(Cornelius et al., 1997; Cornelius, Perkins, Salloum, Thase, & Moss, 1999)
were excluded because outcome was defined as smoking reduction. A
study conducted by Glassman et al. (1990) was excluded because outcome
was based on retrospective recall of smoking cessation.

Ratings of Study Characteristics
We developed a coding scheme that would allow us to describe the
sample of studies in our database as well as to examine in secondary
analyses study characteristics that might help to account for potential
moderating effects of depression on smoking cessation. In addition to the
type of depression assessment (questionnaire, semistructured interview, or
structured interview), studies were rated on three categories of characteristics. The first was methodology, and included nature of sampling, sample
composition, and study design. Nature of sampling was rated as either
clinical (treatment sample), epidemiologic (community random sample), or
sample of convenience (random sample of intact community). Sample
composition was coded as healthy (no current medical or psychiatric
illness), medical (unstable medical condition, such as recent myocardial
infarct), psychiatric (current psychiatric condition, such as alcohol dependence), or mixed (participants with concurrent medical and major psychiatric illness). Design was rated as either cross-sectional or prospective.
We coded for two treatment characteristics: modality and intensity.
Modality was rated as unaided (minimal or no intervention), behavioral
therapy, pharmacotherapy, or combined behavioral therapy and pharmacotherapy. Intensity was rated as either minimal (ⱕ 3 hr total patient–

therapist contact) or intensive (⬎ 3 hr total contact). The third category was
smoking status, where we coded for its definition and how and when it was
assessed. Definition of smoking status was coded as point-prevalent (abstinence at a single time point), continuous (abstinence between initial
quitting and a follow-up time point), or prolonged (sustained abstinence
between two follow-ups). The type of smoking status assessment was
coded as self-report or self-report with biochemical verification. Smoking
cessation outcome was rated as either short- (ⱕ 3 months) or long-term
(ⱖ 6 months). Classification for the definition of smoking status and
smoking cessation outcome was based on recommendations made by the
Society for Research on Nicotine and Tobacco Subcommittee on Abstinence Measures (Hughes et al., 2003).
Studies were coded independently by two reviewers. When there was
disagreement, consensus was reached through a third reviewer. Across
studies and characteristics, there was excellent agreement between raters
(84.6%). The methodological and treatment characteristics of the studies in
the meta-analysis are displayed in the Appendix.

Procedure
Our analytic procedure consisted of five steps and was based on the
procedures recommended by Hedges and Olkin (1985). First, we computed
the effect size, Hedges’s g, for each of the identified studies. Because it was
plausible that the effect of depression on smoking cessation might vary as
a function of length of outcome, we attempted whenever possible to obtain
separate effect sizes for both short- and long-term cessation. Effect sizes
were calculated using the meta-analytic program DSTAT and the following
equation (Johnson, 1989).
g ⫽ 共P E ⫺ P C 兲/S pooled
PE represents the proportion abstinent for the history positives, PC represents the proportion abstinent for history negatives, and Spooled represents
the pooled standard deviation between the two groups. Data for this
computation were available in 12 of 15 studies. For 2 of the 3 remaining
studies (Keuthen et al., 2000; Killen et al., 2000), we obtained groupspecific abstinence rates from the authors. For the 3rd study (Prochazka et
al., 1998), we assigned an effect size estimate of 0.00 and a one-tailed p of
.50 following the recommendation by Rosenthal (1995). For all studies, we
extracted data on point-prevalence abstinence that had been derived on
an intent-to-treat basis. Effect size estimates were weighted by study
sample sizes (weighted effect size ⫽ d⫹). A negative sign indicated lower
abstinence rates for history positive smokers. Next, to determine the
overall strength of the association between depression history and cessation
outcome, we calculated the mean effect size for short- and long-term
abstinence.
We examined the consistency of individual study effect sizes in the third
step. To maintain the assumption of independent sets of effect sizes, we
included only one effect size estimate from each study for each category of
outcome. When a study offered more than one outcome that met our
criteria for either short- (ⱕ 3 months) or long-term cessation (ⱖ 6 months),
we selected the furthest assessment time point that fit within our definition.
For example, if a study assessed abstinence at both 1-week and 1-month
postquit, we selected the 1-month data and coded them as “short-term”
outcome. If an aggregated effect size was found to be heterogeneous,
outlier effects were deleted individually and we recalculated the homogeneity statistic (Qw). Outliers were deleted one at a time until we observed
a homogeneous effect (i.e., variability around the mean is no greater than
that expected from sample error alone).
In the fourth step, we calculated effect sizes separately for females and
males to examine whether gender influenced either the magnitude or
direction of the aggregated effect sizes for either short- or long-term
cessation. Of the 15 studies, 3 reported gender-specific abstinence rates
(Covey et al., 1993; Covey, Glassman, & Stetner, 1999; Hall et al., 1998).
For the 12 studies in which these data were unavailable, we sent a letter to
the authors requesting them. We obtained gender-specific abstinence data

DEPRESSION AND SMOKING CESSATION
for all but 3 studies (Ginsberg et al., 1995; Glassman et al., 1988;
Prochazka et al., 1998). In the final step, we tested whether any of the
methodology or treatment factors were significant moderators of the
depression– outcome relationship. A fixed-effects model was used for all
tests of between-class effects (Qb).

Results
A summary of the coded study characteristics is presented in
Table 1. Studies were predominately clinical trials (93%; n ⫽ 14)
involving “healthy” smokers (87%; n ⫽ 13). Except for the study
by Muñoz, Marin, Posner, and Perez-Stable (1997), all of the
treatment studies excluded smokers with current medical or psychiatric illness. The majority of studies involved intensive interventions (67%; n ⫽ 10) combining cognitive– behavioral therapy
and pharmacotherapy (73%; n ⫽ 11). Biochemically verified abstinence (e.g., expired carbon monoxide) was obtained in most
studies (80%; n ⫽ 12). Most depression assessments were structured interviews (73%; n ⫽ 11). Across the 15 studies, the mean
percentage of smokers with a history of depression was 34%
(SD ⫽ 15.0; range ⫽ 12% to 64%). Overall, 2,984 participants
were involved. Twenty-nine percent of these (n ⫽ 875) were
classified as having a history of depression. Data on treatment drop
out by depression history were available in 5 of 14 treatment
studies (Glassman et al., 1993; Ginsberg et al., 1995; Hall et al.,
1998; Keuthen et al., 2000; Niaura et al., 1999). None showed a
differential dropout.

Table 1
Characteristics of Coded Studies
Variable
Sampling
Clinical
Epidemiological
Design
Prospective
Cross-sectional
Sample
Healthy
Medical
Psychiatric
Mixed
Treatment modality
Unaided
Behavioral treatment
Combined treatment
Treatment intensitya
Minimal
Intensive
Abstinence definition
Point prevalence
Continuous abstinence
Prolonged abstinence
Abstinence assessment
Self-report
Biochemical validation
Type of depression assessment
Single item
Questionnaire
Structured interview
a

No. of studies

%

14
1

93
7

15
0

100
0

13
0
0
2

87
0
0
13

1
3
11

7
20
73

4
10

27
67

15
0
0

100
0
0

3
12

20
80

1
3
11

7
20
73

Numbers do not sum to 15 because Breslau, Kilbey, and Andreski (1993)
was not a treatment study.
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Effect of History of Depression on Smoking Cessation
Contrary to expectations, there was no effect of history of
depression on short-term abstinence, d⫹ ⫽ ⫺.05, 95% confidence
interval (CI) ⫽ ⫺.14, .04, counternull d⫹ ⫽ ⫺.10, p ⫽ .18. The
test of homogeneity revealed a homogeneous effect,
Qw(12) ⫽ 17.37, p ⫽ .18, indicating consistency among the effect
size estimates of short-term abstinence (see Figure 1). Only 2 of 13
studies (Covey et al., 1993; Glassman et al., 1988) supported the
hypothesis that history of depression negatively influences cessation outcome. We observed a similar pattern for long-term abstinence, where only 1 of 12 studies (Glassman et al., 1993) yielded
a significant effect size estimate (see Figure 2). Again, when effect
sizes were aggregated, the effect of depressive history was nonsignificant, d⫹ ⫽ ⫺.06, 95% CI ⫽ ⫺.15, .04, counternull d⫹ ⫽
⫺.12, p ⫽ .18, and homogeneous, Qw(12) ⫽ 13.79, p ⫽ .31.
Results were unchanged when the one nontreatment study
(Breslau, Peterson, Schultz, Chilcoat, & Andreski, 1998) was
excluded from the analysis, d⫹ ⫽ ⫺.05, 95% CI ⫽ ⫺.15, .04, p ⫽
.21. The test of between-class effects revealed nonsignificant differences between short- and long-term outcome, Qb(1) ⬍ 0.00, p ⫽
.99. Sample sizes and intent-to-treat quit rates for short- and
long-term outcome are presented in Table 2.

Analyses of Moderator Effects
Given that women are almost twice as likely as men to experience depression (Weissman et al., 1996), we considered it plausible that gender might influence the magnitude and/or direction of
the association between history of depression and smoking cessation. Gender-specific effect sizes for short- and long-term abstinence were computed using Hedges and Olkin’s formula for
proportion/frequency data (see equation).
For men, when effect sizes were aggregated for short-term
outcome, history of depression did not influence abstinence rates,
d⫹ ⫽ ⫺.01, 95% CI ⫽ ⫺.15, .13, p ⫽ .84. The test of homogeneity revealed a homogeneous overall effect, Qw(10) ⫽ 11.23, p ⫽
.34. We observed the same for long-term abstinence. The overall
effect size was nonsignificant, d⫹ ⫽ ⫺.09, 95% CI ⫽ ⫺.25, .06,
p ⫽ .14, and homogeneous, Qw(8) ⫽ 3.87, p ⫽ .87.
When effect sizes of short-term outcome were aggregated for
women, results revealed a nonsignificant effect of history of depression on abstinence, d⫹ ⫽ .05, 95% CI ⫽ ⫺.07, .17, p ⫽ .37,
that was heterogeneous, Qw(10) ⫽ 18.64, p ⫽ .04. Deletion of one
outlier (Covey et al., 1999) yielded a homogeneous overall effect,
d⫹ ⫽ .07, 95% CI ⫽ ⫺.05, .20, p ⫽ .19, Qw(9) ⫽ 14.73, p ⫽ .10.
The effect for women for long-term cessation also was nonsignificant, d⫹ ⫽ ⫺.05, 95% CI ⫽ ⫺.18, .07, p ⫽ .37, and heterogeneous, Qw(8) ⫽ 24.83, p ⫽ .002. Deletion of two outliers (Covey
et al., 1999; Glassman et al., 1993) yielded a homogeneous effect,
Qw(6) ⫽ 24.83, p ⫽ .05, that remained nonsignificant, d⫹ ⫽ .09,
95% CI ⫽ ⫺.06, .24, p ⫽ .19. Similar to the procedure followed
in the overall analysis, we conducted tests of between-class effects
to examine whether gender moderated the association between
history of depression and smoking cessation. Results of the analysis of short-term abstinence revealed no difference between men
and women in effect size estimates, Qb(1) ⫽ 0.84, p ⫽ .36. For
long-term abstinence, the difference approached significance,
Qb(1) ⫽ 2.79, p ⫽ .09.
We also considered it plausible that the association between
history of depression and smoking cessation may be moderated by
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Figure 1.

Effect size estimates for short-term abstinence (ⱕ 3 months) weighted by sample sizes.

Figure 2.

Effect size estimates for long-term abstinence (ⱖ 6 months) weighted by sample sizes.
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Table 2
Sample Sizes and Intent-to-Treat Quit Rates Across Studies for Smokers Positive (Hx⫹) Versus
Negative (Hx⫺) for History of Depression at Short- and Long-Term Outcome
Short term

Long term

Study

N
(Hx⫹/Hx⫺)

% quit
(Hx⫹/Hx⫺)

Time

% quit
(Hx⫹/Hx⫺)

Time

Glassman et al. (1988)
Covey et al. (1993)
Glassman et al. (1993)
Hall et al. (1994)
Ginsberg et al. (1995)
Hall et al. (1996)
Muñoz et al. (1997)
Breslau et al. (1998)
Hall et al. (1998)
Prochazka et al. (1998)
Covey et al. (1999)
Hayford et al. (1999)
Niaura et al. (1999)a
Killen et al. (2000)
Keuthen et al. (2000)

71 (43/28)
220 (73/147)
300 (113/187)
149 (46/103)
62 (27/35)
201 (44/157)
83 (53/30)
281 (90/191)
199 (65/134)
214 (26/188)
68 (36/32)
615 (114/501)
183 (64/119)
224 (45/179)
114 (36/78)

33/57
22/29
24/30
61/48
48/57
41/35
21/17
—
46/52
—
31/41
32/33
25/19
44/34
25/18

4 week
10 week
10 week
12 week
2 week
12 week
12 week
—
12 week
—
4 week
6 week
4 week
10 week
10 week

—
—
3/13
39/29
15/14
30/29
28/17
19/23
26/34
—
17/25
19/20
—
29/23
8/6

—
—
26 week
52 week
52 week
52 week
26 week
5 year
64 week
26 week
26 week
52 week
—
26 week
26 week

Note. Abstinence rates are presented using the following format: (percentage abstinent for depression history
positive/percentage abstinent for depression history negative). Dashes indicate the data are not available.
a
Sample sizes and quit rates are based on the entire sample of participants who completed the trial (N ⫽ 183),
as opposed to only the subsample (n ⫽ 133) studied in Niaura et al. (1999).

methodological or treatment characteristics. Cell sizes for most of
the proposed moderators were small and unequal (see Table 1). We
analyzed the variables in which there were at least two cells with
greater than two cases. Results showed that the effect of history of
depression on short- or long-term abstinence did not differ as a
function of sample composition, time interval since last depressive
episode, treatment modality or intensity, nature of smoking status,
or depression assessment.

Discussion
A strength of meta-analyses is that they have the potential to
provide an objective appraisal of the empirical evidence (Hedges
& Olkin, 1985). We found that a lifetime history of major depression did not independently increase the risk of either short- or
long-term smoking cessation failure. Moreover, we found that the
influence of depression on abstinence was no greater for female
smokers than male smokers. Although limited by the homogeneity
of study characteristics, as well as the small and unequal sample
sizes, we also observed that none of the methodology or treatment
factors moderated the depression–abstinence relationship.
Our findings indicate that knowing whether a smoker has a
history of depression yields little or no predictive information
regarding his or her ability to stop smoking within the context of
intensive smoking cessation treatment. It remains possible that
recurrent depression, in contrast to single-episode depression,
might have negative implications for smoking cessation. The rationale is that a multiple episode history may reflect a substantial
underlying vulnerability to disorder (Zubin & Spring, 1977).
Single-episode depression, in contrast, may occur serendipitously
even among individuals of low psychopathologic vulnerability, if
they encounter sufficiently major loss or other significant life
stressors. Three studies have distinguished between smokers with
single versus recurrent depression. Glassman et al. (1993) found

that smokers with recurrent depression were at a greater risk for
relapse than those with a single-episode history. In a study by
Covey et al. (1999), women with recurrent depression, but not
men, were at increased risk for relapse. The hypothesis that a
recurrent history of depression, as opposed to single-episode depression, increases risk for poor outcome also was supported in a
recent study by Brown et al. (2001) that tested the efficacy of
mood management-smoking cessation treatment versus standard
treatment in 179 smokers. All participants had a lifetime history of
depression. Among those who received standard treatment, history
of recurrent depression, but not single-episode depression, predicted relapse. Overall, smokers with recurrent depression who
received mood management were more likely to be abstinent than
those who received standard treatment.
Risk for cessation failure among depression prone smokers is
likely conveyed through a combination of enduring trait vulnerability, reflected by a history of recurrent depression, and a vulnerable state, reflected by elevated depressive symptomatology prior
to treatment (Borrelli et al., 1999; Niaura & Abrams, 2001). Future
research should determine the attributes that characterize the depression vulnerable smokers who are at greatest risk for failure. On
the basis of our findings, simply knowing that a smoker has a
history of depression is uninformative regarding his or her ability
to stop smoking. Potentially more informative predictors that warrant
further investigation include recurrence of depression, episode duration or recency, or even specific symptoms (e.g., depressed mood) or
clusters of symptoms (Niaura & Abrams, 2001). Because of possible
differences in rates and symptoms of depression across adulthood
(Karel, 1997), future studies should also consider the influence of age.
Also unanswered is whether current major depression is a significant barrier to smoking cessation. One might expect depressed
patients to be at high risk for cessation failure, given that even low
levels of pretreatment depressive symptomatology predict time to
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relapse (Niaura et al., 2001). However, treatment-related quit rates
among smokers with current depression have rarely been studied.
Depressed smokers are almost always excluded from smoking
cessation treatment studies, especially those involving antidepressant pharmacotherapy. There have been only two published studies
involving smokers with current major depression (Muñoz et al.,
1997; Thorsteinsson et al., 2002). Results of both indicate that
depressed patients may be capable of achieving short-term abstinence at rates comparable to those of nondepressed smokers,
although a question can be raised about the representativeness of
depressed people with sufficient motivation and energy to seek
cessation treatment.
Several limitations should be considered. First, given that the
current meta-analysis involved fixed-effects modeling of a homogeneous sample, our findings generalize only to the types of
studies represented: “healthy” smokers involved in clinical trials of
intensive, combined pharmacological plus psychological interventions. Whether they generalize to smokers with concurrent medical
and/or psychiatric illness, continuous or prolonged abstinence,
cross-sectional studies of the association between depression and
smoking status, or prospective, population-based smoking cessation studies remains to be determined. Second, despite the large
sample of studies identified through the literature search, only a
small number reported an assessment of lifetime history of depression and evaluated its association with smoking cessation. Consequently, the power of our statistical tests was low (.24 for the
analysis of short-term outcome and .23 for that of long-term
outcome). The extent to which this should influence interpretations
of our findings is uncertain. Using the procedures developed by
Hedges and Pigott (2001) for computing the power of statistical
tests in meta-analyses, we estimated that an additional 61 studies,
each involving 198 participants (12,078 overall), would be required for power ⫽ .80. Even if sufficiently powered and statistically significant, it is unlikely that effect sizes of the magnitude we
observed (short-term d⫹ ⫽ ⫺.05, long-term d⫹ ⫽ ⫺.06) would be
meaningful clinically. Third, only 4 of 15 studies (Glassman et al.,
1993; Hall, Muñoz, & Reus, 1994, Hall et al., 1996, 1998) included in our meta-analysis were designed to test whether history
of depression influences cessation outcome. Only 1 (Killen et al.,
2000) was designed to detect gender differences in outcome.
Studies based on post hoc analyses of outcome data, as opposed to
those designed to test the moderating influence of third variables
using stratified randomization, have the potential to be misleading
(Killen, Fortmann, Varady, & Kraemer, 2002). Future studies
examining the moderating influences of depression and gender on
cessation outcome should stratify randomization on these factors.
Refining understanding of whether and how depressionvulnerable smokers may be at heightened risk for smoking cessation failure is especially crucial given the extent to which both
clinicians and researchers have accepted the early, but most often
unreplicated, finding that a history of depression is a barrier to
quitting smoking. A negative consequence of this assumption from
a research perspective has been the premature focus on developing
intensive, specialized treatments for all smokers with a positive
history of depression. From a clinical perspective, it is possible
that many history-positive smokers have been either encouraged to
pursue unnecessarily intensive treatments or indirectly discouraged from quitting altogether, even though they were as likely as
history-negative smokers to achieve abstinence.
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Appendix
Summary of Methodology and Treatment Characteristics for Studies Included in the Meta-Analysis
Study

Sampling

Sample

Entry
smoking

Glassman et al. (1988)
Covey et al. (1993)
Glassman et al. (1993)
Hall et al. (1994)
Ginsberg et al. (1995)
Hall et al. (1996)
Muñoz et al. (1997)
Breslau et al. (1998)
Hall et al. (1998)
Prochazka et al. (1998)
Covey et al. (1999)
Hayford et al. (1999)
Niaura et al. (1999)
Keuthen et al. (2000)
Killen et al. (2000)

clinical
clinical
clinical
clinical
clinical
clinical
clinical
epi
clinical
clinical
clinical
clinical
clinical
clinical
clinical

healthy
healthy
healthy
healthy
healthy
healthy
mixed
mixed
healthy
healthy
healthy
healthy
healthy
healthy
healthy

ⱖ20 cigs/daya
ⱖ20 cigs/day
ⱖ20 cigs/day
⬎10 cigs/day
ⱖ10 cigs/day
ⱖ10 cigs/day
ⱖ3 cigs/day
none
⬎10 cigs/day
ⱖ10 cigs/day
ⱖ20 cigs/day
ⱖ15 cigs/day
daily
dailyb
ⱖ10 cigs/day

Depression
exclusion

Abstinence
assessment

Treatment
modality

Treatment
intensity

Depression
assessment

current
months
months
months
months
months
none
none
⬍3 months
current
current
current
current
current
current

self-report
biochemical
biochemical
biochemical
biochemical
biochemical
biochemical
self-report
biochemical
biochemical
biochemical
self-report
biochemical
biochemical
biochemical

combined
combined
combined
combined
behavioral
combined
behavioral
unaided
combined
combined
combined
combined
behavioral
combined
combined

intensive
intensive
intensive
intensive
intensive
intensive
minimal
no treatment
intensive
intensive
intensive
minimal
minimal
intensive
minimal

struct interview (SADS)
struct interview (SCID)
struct interview (SCID)
struct interview (DIS)
struct interview (DIS)
self-report (comp DIS)
struct interview (DIS)
struct interview (DIS)
self-report (comp DIS)
self-report (comp DIS)
struct interview (SADS)
struct interview (SCID)
two-item self-report
struct interview (SCID)
struct interview (SCID)

⬍6
⬍6
⬍6
⬍6
⬍3

Note. Entry smoking ⫽ required or observed smoking rate; biochemical ⫽ biochemical confirmation of self-reported smoking status; depression
exclusion ⫽ exclusion criteria for time interval since last depressive episode. cigs ⫽ cigarettes; struct ⫽ structured; SADS ⫽ Schedule for Affective
Disorders and Schizophrenia; DIS ⫽ Diagnostic Interview Scale; SCID ⫽ Structured Clinical Interview for the DSM–IV; comp DIS ⫽ computerized
version of the DIS; epi ⫽ epidemiological.
a
Also required 50% reduction in cigs/day by quit date. b Also required expired carbon monoxide levels ⱖ 8 parts per million.

Received April 3, 2002
Revision received November 18, 2002
Accepted November 22, 2002 䡲

